Dr. Robert T. Dorr, PhD
Biography & Research Background
Robert T. Dorr, PhD (deceased), was a Professor in the College of Medicine (Pharmacology Department) at the University of Arizona. He led the therapeutic development scientific program and conducted the initial pilot Phase I clinical trials involving human volunteers to evaluate the safety, tanning activity, and side effects of Melanotan II. Key publications: 'Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study' (1996), 'Increased Eumelanin Expression and Tanning is Induced by a Superpotent Melanotropin in Humans' (2000), and 'Melanocortin peptide therapeutics: Historical milestones' (2006). Robert Dorr is referenced as a foundational pharmacologist in melanocortin peptide research. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Robert T. Dorr, PhD is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Robert T. Dorr, PhD is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.